MaaT Pharma SA (MAAT.PA) News
Track canonical SquawkNews coverage tagged to MAAT.PA, MaaT Pharma SA. This hub brings together deduplicated headlines about paris, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re — examination
For best results when printing this announcement, please click on link below: MaaT Pharma Provides Update on MaaT013 (Xervyteg(®)) Potential Development Plan Following CHMP Negative Opinion After Re-examination The Commi
CENTRAL_BANK | Sep 18, 2026, 05:32 AM UTC
L
MaaT Pharma says EU drug panel maintains negative opinion on Xervyteg conditional approval
EMA’s CHMP upheld a negative opinion on conditional approval for Xervyteg in refractory gastrointestinal acute graft-versus-host disease. Regulators cited insufficient benefit-risk evidence from the single-arm dataset, k
REGULATION | Sep 18, 2026, 05:32 AM UTC